Alumis (ALMS) Interest Expenses (2023 - 2026)
Alumis (ALMS) posted quarterly Interest Expenses of $1.9 million for Q4 2025, up 56.91% year-over-year from $1.2 million in Q4 2024, and down 88.77% quarter-over-quarter from $17.1 million in Q3 2025.
Alumis (ALMS) Interest Expenses (2023 - 2026) Analysis & Trends
Alumis (ALMS) has reported Interest Expenses for 3 consecutive years, with $1.9 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Interest Expenses rose 56.91% year-over-year to $1.9 million; the TTM figure through Dec 2025 stood at $5.7 million (up 24.53% YoY), while the FY2025 annual figure was $293.0 million, up 2376.15% from the prior year.
- Interest Expenses slipped to $1.9 million in Q4 2025 per ALMS's latest filing, from $17.1 million in the prior quarter.
- Across five years, Interest Expenses topped out at $56.9 million in Q2 2025 and bottomed at $805000.0 in Q3 2023.
- Historically, Interest Expenses has averaged $14.1 million across 3 years, with a median of $3.5 million in 2025.
- Annual changes were most pronounced in 2024 — Interest Expenses jumped 6060.5% — and 2025, when it plunged 65.55%.
- Alumis' Interest Expenses stood at $1.2 million in 2023, then climbed by 5.16% to $1.2 million in 2024, then soared by 56.91% to $1.9 million in 2025.
- Business Quant data shows ALMS's Interest Expenses at $1.9 million in Q4 2025, $17.1 million in Q3 2025, and $56.9 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Alumis | 3.25 Bn | 2.75 Bn | - | 50.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 50.78 Mn |
| Jun 30, 2026 | 50.78 Mn |
| Dec 31, 2025 | 1.92 Mn |
| Dec 31, 2025 | 1.92 Mn |
| Sep 30, 2025 | 17.08 Mn |
| Sep 30, 2025 | 17.08 Mn |
| Jun 30, 2025 | 56.92 Mn |
| Jun 30, 2025 | 56.92 Mn |
| Mar 31, 2025 | 5.09 Mn |
| Mar 31, 2025 | 5.09 Mn |
| Dec 31, 2024 | 1.22 Mn |
| Dec 31, 2024 | 1.22 Mn |
| Sep 30, 2024 | 49.59 Mn |
| Sep 30, 2024 | 49.59 Mn |
| Jun 30, 2024 | 5.74 Mn |
| Jun 30, 2024 | 5.74 Mn |
| Mar 31, 2024 | 1.35 Mn |
| Mar 31, 2024 | 1.35 Mn |
| Dec 31, 2023 | 1.16 Mn |
| Dec 31, 2023 | 1.16 Mn |